Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Risankizumab Dose A · 1 trial · 1 indication
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
| Arm | Type | Description |
|---|---|---|
| Risankizumab Dose A | EXPERIMENTAL | Participants will receive subcutaneous dose of risankizumab dose A. |
| Risankizumab Dose B | EXPERIMENTAL | Participants will receive subcutaneous dose of risankizumab dose B. |
| Name | Type | Description |
|---|---|---|
| Risankizumab Dose A | DRUG | Prefilled Syringe |
| Risankizumab Dose B | DRUG | Prefilled Syringe |
Inclusion Criteria: \- Body weight greater than 40 kg and less than 100 kg at screening and upon initial confinement. Exclusion Criteria: * Previous exposure to any anti-interleukin-12/23 or anti-interleukin-23 treatment. * Intention to perform strenuous exercise to which the participant is unacc...
Risankizumab Dose A is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial evaluating its relative bioavailability in healthy adult participants. The drug is not approved for any indication and remains under clinical investigation.
Risankizumab Dose A is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. AbbVie is conducting clinical trials to evaluate the drug's properties in healthy volunteers.
Risankizumab Dose A is in Phase 1 clinical development. It has completed one Phase 1 trial, and there are no active trials currently ongoing. The drug remains investigational and has not been approved by regulatory authorities.
Risankizumab Dose A has one completed clinical trial, NCT05567029, titled "Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers." This Phase 1 study enrolled 198 participants in the United States and was completed.
Risankizumab Dose A is a specific formulation or presentation of risankizumab being studied for its relative bioavailability. The trial NCT05567029 compares two drug product presentations of risankizumab in healthy volunteers to evaluate how they are absorbed and processed by the body.